El interés en corto de BioVie da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de BioVie. Los datos de interés en corto se actualizan cada dos semanas.

BioVie (NASDAQ:BIVI) Bolsa, Informe de interés en corto

BioVie

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

BioVie Inc

BIVICTRIX THERAPEUTICS PL by BIVICTRIX THERAPEUTICS PLC

BiVictriX Therapeutics PLC

Bill Gates doesn't shy away from paying taxes. In fact, he <a href="https://www.benzinga.com/personal-finance/24/07/39657043/bill-gates-wants-to-pay-more-in-taxes-ive-been-disproportionately-rewarded-while-many-others-who">thinks he should be paying more – </a>a lot more. But if he feels that way, why doesn't the multibillionaire voluntarily hand over a bigger slice of his fortune to Uncle Sam?&nbsp;
It's a question critics love to ask and Gates has been clear about his stance. In a 2019 end-of-the-year GatesNotes blog post, he addressed the question: "People pay taxes as an obligation of law and citizenship, not out of charity."
Don't Miss:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
This isn't some new talking point for Gates. For years, he's publicly advocated for a fairer, more progressive tax system. Back in the 2019 blog post, he pointed out what he sees as a fundamental problem: "The U.S. government simply does not bring in enough money to meet its obligations. This isn't a value judgment; it's just a fact." And Gates believes the wealthiest Americans – including himself – should be doing more to close that gap.
It's not just lip service, either. Gates and his father were early champions of raising the federal estate tax and they supported creating a state income tax in Washington, one of the most regressive tax states in the country. The reasoning is simple: Gates doesn't believe wealth and power should be concentrated in families just because they happened to hit the jackpot a generation ago. "A dynastic system where you can pass vast wealth along to your children is not good for anyone," he's said, explaining why he and Melinda plan to give most of their fortune to charity instead of leaving it to their kids.
See Also: Deloitte's fastest-growing software company partnered with Amazon, Walmart &amp; Target announces the deadline to invest this year is 12/20. – <a href="https://www.benzinga.com/money/mode-mobile-2">Last Chance to get 4,000 of its pre-IPO shares for just $0.26/share!</a>
Still, the question persists: Why not lead by example and pay more than required? Gates has a straightforward answer. He argues that taxes aren't meant to be optional. Voluntary contributions, while noble, aren't a scalable solution to funding the public good. "If Melinda and I signed over our foundation's entire endowment to the state of California, it wouldn't be enough to fund their public schools for even one year," he wrote. For Gates, a robust tax system – designed to be fair and consistent – is the only way to address inequality and meet the government's obligations.
He's particularly critical of how the current tax system favors wealth over work. Capital gains, which comprise a large portion of income for the wealthiest Americans, are taxed at just 20%, while labor income can be taxed up to 37%. That discrepancy, Gates argues, is unfair. "I don't see any reason to favor wealth over work the way we do today," he said, suggesting that capital gains taxes should be raised to match income taxes.
Trending: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
Gates also supports closing loopholes in the estate tax, removing caps on Medicare taxes and taxing long-held fortunes that often escape scrutiny. He's quick to point out that these changes wouldn't just be symbolic gestures – they'd help <a href="https://www.benzinga.com/personal-finance/24/12/42396804/could-the-super-catch-up-be-your-ticket-to-a-richer-retirement-starting-in-2025-60-year-olds-can-save-an-extra-11250">create a more balanced system</a> where everyone contributes their fair share.
But Gates isn't blind to the importance of incentives. He's careful to stress that taxes shouldn't be raised so high that they discourage innovation. After all, when he and Paul Allen started Microsoft in the 1970s, the top marginal tax rate was nearly double what it is today and it didn't stop them from building one of the world's most valuable companies. In his view, there's still plenty of room to increase taxes on the wealthy without stifling entrepreneurship or economic growth.
Trending: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
While Gates has no intention of writing unsolicited checks to the IRS, his commitment to giving back is clear. Through philanthropy, he and Melinda focus on tackling global challenges like health, education and climate change – areas where private foundations can often take risks that governments or corporations can't. As he sees it, philanthropy and fair taxation aren't mutually exclusive; they're complementary ways of <a href="https://www.benzinga.com/money/are-you-rich">addressing inequality and driving progress</a>.
Ultimately, Gates believes <a href="https://www.benzinga.com/news/24/12/42438799/bill-gates-predicts-ai-in-the-workforce-will-lead-to-so-much-leisure-time-but-itll-create-a-what-do-we-do-with-all-that-time-problem">real change</a> won't come from one billionaire's checkbook. It has to come from rethinking the system itself. "We've updated our tax system before to keep up with changing times," he wrote, "and we need to do it again, starting with raising taxes on people like me." For Gates, it's not about the size of his contribution – it's about creating a system where everyone pays their fair share, not out of charity, but out of obligation.
Read Next:
<ul>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">The deadline to invest and receive your shares this year is 12/20. Join 30,000+ shareholders and invest at $0.26/share today.</a></li>
</ul>

Personal Finance

Bill Gates Answers Why He Doesn't Just Voluntarily Pay More In Taxes – 'People Pay Taxes As An Obligation Of Law … Not Out Of Charity'

Raymond James analyst Simon Leopold maintains Applied Optoelectronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) with a Outperform and raises the price target from $17 to $39.

News

Price Target

Analyst Ratings

AAOI

Raymond James Maintains Outperform on Applied Optoelectronics, Raises Price Target to $39

WIIM

ECARX Holdings shares are trading higher after the company announced a plan to repurchase up to $20 million of its ordinary shares through September 30, 2025.

JP Morgan analyst Matthew Boss maintains Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) with a Overweight and raises the price target from $201 to $204.

JP Morgan Maintains Overweight on Abercrombie & Fitch, Raises Price Target to $204

WEX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEX#NYSE">WEX</a>) has outperformed the market over the past 15 years by 31.59% on an annualized basis producing an average annual return of 43.27%. Currently, WEX has a market capitalization of $6.66 billion. 
Buying $1000 In WEX: If an investor had bought $1000 of WEX stock 15 years ago, it would be worth $219,844.16 today based on a price of $167.45 for WEX at the time of writing.
<h3>WEX's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734711614_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

JP Morgan analyst Rajat Gupta maintains CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) with a Underweight and raises the price target from $70 to $72.

JP Morgan Maintains Underweight on CarMax, Raises Price Target to $72

TD Cowen analyst Daniel Chan upgrades BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) from Hold to Buy and raises the price target from $3.25 to $4.

Upgrades

TD Cowen Upgrades BlackBerry to Buy, Raises Price Target to $4

JP Morgan analyst Brian Ossenbeck maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Overweight and raises the price target from $366 to $370.

JP Morgan Maintains Overweight on FedEx, Raises Price Target to $370

Mastercard's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) short percent of float has risen 5.48% since its last report. The company recently reported that it has 6.29 million shares sold short, which is 0.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.31 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Mastercard Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734711325_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Mastercard has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Mastercard's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Mastercard's peer group average for short interest as a percentage of float is 4.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Mastercard's Recent Short Interest

Viking Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NYSE">VKTX</a>) short percent of float has risen 6.35% since its last report. The company recently reported that it has 18.07 million shares sold short, which is 21.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Viking Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734711319_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Viking Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Viking Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Viking Therapeutics's peer group average for short interest as a percentage of float is 13.65%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

VKTX

Looking Into Viking Therapeutics's Recent Short Interest

Lumentum Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NYSE">LITE</a>) short percent of float has risen 5.18% since its last report. The company recently reported that it has 11.15 million shares sold short, which is 21.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.96 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lumentum Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734711315_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lumentum Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lumentum Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lumentum Holdings's peer group average for short interest as a percentage of float is 6.05%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

LITE

Peering Into Lumentum Holdings's Recent Short Interest

Macro Economic Events

Market Summary

Economics

General

Benzinga Market Summary: Novo Nordisk Falls On Weight Loss Data, Shares Of Competitor Lilly Rise, S&P Continues Higher

DXCM

Shares of glucose monitoring stocks are trading higher following weaker-than-expected weight loss data from Novo Nordisk.

Pyxis Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) announced on Thursday, a portfolio prioritization, focusing resources on advancing its <a href="https://www.benzinga.com/pressreleases/24/12/g42603862/pyxis-oncology-announces-portfolio-prioritization-focusing-resources-on-its-lead-clinical-program-" target="_blank" rel="noreferrer noopener">lead clinical program, PYX-201</a>.
Pyxis Oncology&#8217;s second clinical program, PYX-106, is being deprioritized to allocate resources toward advancing the lead asset, PYX-201.
As a result, Pyxis Oncology has decided to suspend further clinical investment in PYX-106, which was in-licensed from Biosion Inc., with Biosion retaining rights for Greater China.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42113042/pyxis-oncologys-cancer-drug-progress-stirs-analyst-concerns" rel="noreferrer noopener">Pyxis Oncology&#8217;s Cancer Drug Progress Stirs Analyst Concerns</a>
In November, Pyxis Oncology reported preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating its safety and efficacy in multiple solid tumor types.
Among patients with HNSCC, PYX-201 achieved a confirmed 50% objective response rate (ORR), including one complete response and a disease control rate (DCR) of 100% in six heavily pretreated HPV-positive and HPV-negative evaluable patients with a median of four prior lines of therapy.
Across six solid tumor types of interest at therapeutically active dose levels, including HNSCC, ovarian, non-small cell lung cancer (NSCLC), HR+/HER2- breast cancer, triple-negative breast cancer (TNBC) and sarcoma, PYX-201 (n=31) achieved a 26% ORR in the Phase 1 trial, with dose-dependent responses observed.
The portfolio prioritization further supports a development plan for PYX-201 in several dose expansion studies, including monotherapy in 2/3L HNSCC, in combination with pembrolizumab in 1/2L+ HNSCC, and pembrolizumab combination studies in other solid tumors including HR+/HER2- and triple-negative breast cancer.
Preliminary data from these cohorts are expected in the second half of 2025 and the first half of 2026.
&#8220;Given the historical development challenges associated with anti-siglec-15 antibodies, we believe that the Street expectations were low heading into the initial data readout for PYX-106,&#8221; said the William Blair analyst.
The company&#8217;s current cash position is expected to fund its planned monotherapy and combination therapy trials of PYX-201 into the second half of 2026.
The analyst says it supports management's decision to stop investing in the program. While PYX-201 showed some activity, it likely won't significantly change head and neck cancer treatment.
PYXS Price Action: PYXS Oncology stock is up 1.30% at $1.56 at publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42615874/why-is-cancer-focused-aadi-bioscience-stock-trading-higher-on-friday" target="_blank" rel="noreferrer noopener">Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?</a></li>
</ul>
This image was created using artificial intelligence MidJourney.

Analyst Color

Biotech

Health Care

PYXS

Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move

SNPX

Synaptogenix shares are trading higher after the company announced it formed an independent Special Committee to explore strategic opportunities.

SCHL

Scholastic shares are trading lower after the company on Thursday reported worse-than-expected Q2 financial results.

BlackBerry shares are trading higher following Q3 financial results.

IONQ

IonQ shares are trading higher after Craig-Hallum raised its price target on the stock from $22 to $45 while maintaining a Buy rating.

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $80 price target.

Reiteration

ARWR

HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $80 Price Target

Looking for <a href="https://www.benzinga.com/trading-ideas/dividends">steady cash flow</a> in 2025? JPMorgan analysts have spotlighted four income-generating stock picks that offer dividend appeal and potential price upside. 
These are: Annaly Capital Management Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NLY#NYSE">NLY</a>), Corning Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>), Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) and HA Sustainable Infrastructure Capital Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HASI#NYSE">HASI</a>).
Here are the details on their top picks.
<h2 class="wp-block-heading">Annaly Capital</h2>
With a hefty forward dividend yield of 13.85% (per <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122024&amp;t=be2bearmibe3na1">Benzinga Pro</a> data), Annaly Capital shines as a beacon for income seekers. 
Analyst Richard Shane expects the mortgage REIT to benefit from a gradual yield curve steepening and rising MBS prices as quantitative tightening eases. 
Trading near $19.76, NLY is viewed as a stable dividend play, supported by mid-teen ROEs and rising interest spreads, according to the analyst. His price target for 2025 is $20.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/price-target/24/12/42615289/wall-streets-most-accurate-analysts-weigh-in-on-3-materials-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Materials Stocks Delivering High-Dividend Yields</a>
<h2 class="wp-block-heading">Corning</h2>
Known for its innovation in glass and fiber optics, Corning offers more than shiny screens. 
Its modest 2.38% yield may seem subdued, but JPMorgan's Samik Chatterjee says this tech titan is poised for high-single-digit revenue growth. 
Riding on data center demand, telecom recovery, and AI-driven innovation, Corning's stock—currently at $48.18—has room to climb to $60 by the end of 2025, the analyst says.
<h2 class="wp-block-heading">Energy Transfer</h2>
Pipeline powerhouse Energy Transfer is turning heads with a forward dividend yield of 7.06%. 
Analyst Jeremy Tonet sees untapped value in its discounted EV/EBITDA ratio compared to peers. 
With fundamentals like Permian egress and natgas logistics firing on all cylinders, ET, trading at $18.70, appears poised to reach Tonet's $23 target, presenting a compelling opportunity for midstream investors.
<h2 class="wp-block-heading">HASI</h2>
Sustainability meets income in Hannon Armstrong Sustainable Infrastructure Capital. HASI's 6.29% yield sweetens the deal for this eco-friendly investment.
JPMorgan's Mark Strouse predicts a brighter outlook thanks to its KKR partnership and investment-grade rating. With shares at $28.72, Strouse forecasts a $42 price by 2025 as HASI reduces its reliance on public capital raises and executes on stable spreads.
Whether you're chasing high yields or balanced growth, these four income plays could be the backbone of your 2025 portfolio. 
From Annaly's robust dividends to Corning's AI-driven potential, JPMorgan's picks are all about turning steady streams into rivers of returns.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/12/42612794/djt-stock-plummets-over-5-following-trumps-stake-transfer-heres-more">DJT Stock Plummets Over 5% Following Trump&#8217;s Stake Transfer: Here&#8217;s More</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

REIT

Dividends

Real Estate

Hannon Armstrong Sustainable Infrastructure Capital

HASI

4 Dividend Picks For 2025: JPMorgan's Top Income Stocks To Energize Your Portfolio

BioVie ( ($BIVI) ) just unveiled an update. BioVie Inc. announced a direct stock offering and a private placement, aiming to raise approximately $6...

BioVie Announces Stock Offering and Private Placement

An announcement from BioVie ( ($BIVI) ) is now available. BioVie Inc. has announced the successful closing of a registered direct offering and conc...

BioVie Secures $6.66 Million Through Direct Offering

BioVie (BIVI) announced the pricing of a registered direct offering of 2.667M shares of its common stock priced at-the-market under Nasdaq rules at...

BioVie 2.667M share registered direct offering priced at $2.25

An update from BioVie ( ($BIVI) ) is now available. BioVie Inc., a clinical-stage company, has announced a registered direct offering and concurren...

BioVie Announces $6 Million Stock Offering and Placement

BioVie ( ($BIVI) ) has provided an update. BioVie Inc., a clinical-stage company developing treatments for chronic conditions, has successfully clo...

BioVie Raises $6 Million in Strategic Funding

BioVie (BIVI) announced the pricing of a registered direct offering of 1,146,000 shares of its common stock priced at-the-market under Nasdaq rules...

BioVie 1.15M share registered direct offering priced at $2.83

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGS – VF Corp. (VFC) up 21.5% F5 Networks (FFIV...

Closing Bell Movers: VF Corp. surges after quarterly results

An announcement from BioVie ( ($BIVI) ) is now available. BioVie Inc. announced the successful closing of its registered direct offering, raising $...

BioVie Raises $3.24 Million in Direct Offering

BioVie (BIVI) announced that the upcoming PD-202 A Double-Blind, Randomized, Placebo-controlled, Study of Bezisterim in Subjects with Early Parkins...

BioVie says Parkinson's Disease clinical trial is fully funded

BioVie files to sell 7.71M shares of common stock for holders

BIVI

CDNS

FFIV

TREX

Financing

Press Releases

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

Join BioVie's Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioVie Inc. Announces Closing of Registered Direct Offering

BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded

BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

Comments

BioVie

Interés en corto

BioVie (NASDAQ:BIVI) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL